[약업신문] C & Palm opens a new era of painless anticancer drugs

A pain-free anti-cancer drug has been developed to treat cancer without causing pain to the patient at the highest non-toxic dose (NOAEL) that does not cause toxicity to the body.

Jung Hyun-bum) announced that the validity of the anticancer drug candidate (CP-727) and preclinical results were confirmed at the 2018 Global Bio Conference (GBC2018) organized by the Korea Food and Drug Administration on June 29th. ] The anti-cancer drug "pain free" is the most nontoxic dose of cancer drugs for cancer patients to treat pain without pain, meanwhile, beyond the maximum non-toxic limit of drug treatment

The currently prescribed anti-cancer drugs are administered to patients at doses up to several tens of times the "maximum non-toxic dose". (Nab-Paclitaxel), which is a typical anti-cancer drug used in pancreatic cancer, is administered approximately 40 times the maximum non-toxic dose and approximately 30 times the amount of Taxol (ingredient name Paclitaxel) used for treatment of ovarian cancer.

According to the company, the new drug, called "Pain-free Cancer Drug", is a new drug that can be used to treat cancer,

In particular, the new drug has been shown to be effective against cancer, because it overcomes the toxic effects of anticancer drugs and its side effects and induce cancer deaths within the maximum limit of non-toxic dose. It is a combination of docetaxel (docetaxel), which is a cure for various cancers such as bad cancer and lung cancer, and an inorganic polymer whose release is as low as 3%, resulting in little toxicity or side effects. (TTR) is 10 times higher than non-cancerous tissue, explained the company.

Following the announcement soon to selected clinical organizations (CRO) will be allowed to apply for the clinic treatment sikyak (DNR deposit). This clinical trial is expected to enter the global clinical phase 1 / 2a of docetaxel, bad cancer, stomach cancer, lung cancer, prostate cancer and pancreas, one of the eight types of cancer

"The pain experienced during chemotherapy is due to the toxicity of the anticancer drugs, and because of this toxicity, the patient is unable to administer a sufficient dose, resulting in a metastasis or a Cancer Resistance "and"

On the other hand, this anti-cancer drug is supported by the health and medical technology research and development project of the Ministry of Health and Welfare, and is a Preclinical institute such as Chemon, Ewha Womans University College of Pharmacy, and has confirmed its efficacy and maximum non-toxic capacity.